Empagliflozin for type 2 diabetes mellitus: An overview of phase 3 clinical trials

Current Diabetes Reviews

Volumn 12, Issue 4, 2016, Pages

  Levine, Matthew J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Empagliflozin; Phase 3; SGLT2 inhibitor; Sodium glucose cotransporter 2; Type 2 diabetes mellitus

Indexed keywords

EMPAGLIFLOZIN; GLYCOSYLATED HEMOGLOBIN; INSULIN; LINAGLIPTIN; METFORMIN; PIOGLITAZONE; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SULFONYLUREA; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; BIOLOGICAL MARKER; GLUCOSIDE; HEMOGLOBIN A1C PROTEIN, HUMAN; SLC5A2 PROTEIN, HUMAN; SODIUM GLUCOSE COTRANSPORTER 2;

ADD ON THERAPY; CARDIOVASCULAR MORTALITY; CORONARY ARTERY DISEASE; DEHYDRATION; DIABETIC KETOACIDOSIS; DRUG ABSORPTION; DRUG EFFICACY; DRUG EXCRETION; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; FRACTURE; FUNGAL GENITAL INFECTION; GERIATRIC PATIENT; GLYCEMIC CONTROL; HEART DISEASE; HEART FAILURE; HOSPITALIZATION; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOGLYCEMIA; INSULIN TREATMENT; JAPANESE (PEOPLE); KIDNEY DISEASE; LABORATORY TEST; MALIGNANT NEOPLASM; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OSMOTIC DIURESIS; PHARMACEUTICAL CARE; PHARMACODYNAMICS; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SYSTOLIC BLOOD PRESSURE; URINARY TRACT INFECTION; WEIGHT REDUCTION; ABNORMAL LABORATORY RESULT; AGED; BLOOD PRESSURE; BONE INJURY; EVIDENCE BASED PRACTICE; FUTUROLOGY; HYPOVOLEMIA; KIDNEY FAILURE; PHASE 2 CLINICAL TRIAL (TOPIC); PILL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; VULNERABLE POPULATION; WEIGHT CHANGE; ANTAGONISTS AND INHIBITORS; BLOOD; CHEMICALLY INDUCED; DRUG EFFECT; FEMALE; GLUCOSE BLOOD LEVEL; KIDNEY PROXIMAL TUBULE; MALE; METABOLISM; MORTALITY; RISK FACTOR; TREATMENT OUTCOME;

BENZHYDRYL COMPOUNDS; BIOMARKERS; BLOOD GLUCOSE; CLINICAL TRIALS, PHASE III AS TOPIC; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCOSIDES; GLYCATED HEMOGLOBIN A; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; KIDNEY TUBULES, PROXIMAL; MALE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; SODIUM-GLUCOSE TRANSPORTER 2; TREATMENT OUTCOME;

EID: 85009081205     PISSN: 15733998     EISSN: 18756417     Source Type: Journal    
DOI: 10.2174/1573399812666160613113556     Document Type: Review

References (74)

1. DeFronzo RA. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009;58(4):773-95.
2. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015;38(1):140-9.
3. UK Prospective Diabetes Study (UKPDS) Group. Intensive bloodglucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352(9131):837-53.
4. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321(7258):405-12.
5. Gerich JE. Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications. Diabet Med 2010;27(2):136-42.
6. Wright EM, Loo DD, Hirayama BA. Biology of human sodium glucose transporters. Physiol Rev 2011;91(2):733−94.
7. Abdul-Ghani MA, DeFronzo RA. Inhibition of renal glucose reabsorption: a novel strategy for achieving glucose control in type 2 diabetes mellitus. Endocr Pract 2008;14(6):782-90.
8. Wilding JP. The role of the kidneys in glucose homeostasis in type 2 diabetes: clinical implications and therapeutic significance through sodium glucose co-transporter 2 inhibitors. Metabolism 2014;63(10):1228-37.
9. List JF, Whaley JM. Glucose dynamics and mechanistic implications of SGLT2 inhibitors in animals and humans. Kidney Int Suppl 2011(120):S20-7.
10. Handelsman Y. Potential place of SGLT2 inhibitors in treatment paradigms for type 2 diabetes mellitus. Endocr Pract 2015;21(9):1054-65.
11. Poole RM, Dungo RT. Ipragliflozin: first global approval. Drugs 2014;74(5):611-7.
12. Poole RM, Prossler JE. Tofogliflozin: first global approval. Drugs 2014;74(8):939-44.
13. Markham A, Elkinson S. Luseogliflozin: first global approval. Drugs 2014;74(8):945-50.
14. Merck Sharp & Dohme Corporation and Pfizer. Cardiovascular outcomes following treatment with ertugliflozin in participants with type 2 diabetes mellitus and established vascular disease (MK-8835-004). ClinicalTrials.gov Identifier: NCT01986881. Available from: https://clinicaltrials.gov/ct2/show/NCT01986881. Accessed: 21 December 2015.
15. Sands AT, Zambrowicz BP, Rosenstock J, et al. Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, as adjunct therapy to insulin in type 1 diabetes. Diabetes Care 2015;38(7):1181-8.
16. Scheen AJ. Pharmacokinetic and pharmacodynamic profile of empagliflozin, a sodium glucose co-transporter 2 inhibitor. Clin Pharmacokinet 2014;53(3):213-225.
17. Grempler R, Thomas L, Eckhardt M, et al. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Diabetes Obes Metab 2012;14(1):83-90.
18. Chen LZ, Jungnik A, Mao Y, et al. Biotransformation and mass balance of the SGLT2 inhibitor empagliflozin in healthy volunteers. Xenobiotica 2015;45(6):520-9.
19. Seman L, Macha S, Nehmiz G, et al. Empagliflozin (BI 10773), a potent and selective SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin Pharmacol Drug Dev 2013;2(2):152-161.
20. Heise T, Seman L, Macha S, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple rising doses of empagliflozin in patients with type 2 diabetes mellitus. Diabetes Ther 2013;4(2):331-45.
21. Heise T, Seewaldt-Becker E, Macha S, et al. Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes. Diabetes Obes Metab 2013;15(7):613-21.
22. Macha S, Rose P, Mattheus M, et al. Pharmacokinetics, safety and tolerability of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with hepatic impairment. Diabetes Obes Metab 2014;16(2):118-23.
23. Macha S, Mattheus M, Halabi A, Pinnetti S, Woerle HJ, Broedl UC. Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment. Diabetes Obes Metab 2014;16(3):215-22.
24. Häring HU, Merker L, Seewaldt-Becker E, et al. Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care 2014;37(6):1650-9.
25. Häring HU, Merker L, Seewaldt-Becker E, et al. Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care 2013;36(11):3396-404.
26. Kovacs CS, Seshiah V, Merker L, et al. Empagliflozin as add-on therapy to pioglitazone with or without metformin in patients with type 2 diabetes mellitus. Clin Ther 2015;37(8):1773-88 e1.
27. Kovacs CS, Seshiah V, Swallow R, et al. Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial. Diabetes Obes Metab 2014;16(2):147-58.
28. Ridderstråle M, Andersen KR, Zeller C, Kim G, Woerle HJ, Broedl UC. Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial. Lancet Diabetes Endocrinol 2014;2(9):691-700.
29. Roden M, Weng J, Eilbracht J, et al. Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol 2013;1(3):208-19.
30. Rosenstock J, Jelaska A, Zeller C, Kim G, Broedl UC, Woerle HJ. Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab 2015;17(10):936-48.
31. Barnett AH, Mithal A, Manassie J, et al. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 2014;2(5):369-84.
32. Tikkanen I, Narko K, Zeller C, et al. Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension. Diabetes Care 2015;38(3):420-8.
33. Chilton R, Tikkanen I, Cannon CP, et al. Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes. Diabetes Obes Metab 2015;17(12):1180-93.
34. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373(22):2117-28.
35. Rosenstock J, Jelaska A, Frappin G, et al. Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes. Diabetes Care 2014;37(7):1815-23.
36. Boehringer Ingelheim Pharmaceuticals Inc. JARDIANCE® (empagliflozin) tablets, for oral use prescribing information (12/2015). Available from: http://www.accessdata.fda.gov/ drugsatfda_docs/label/2015/204629s007lbl.pdf. Accessed: 21 December 2015.
37. Araki E, Tanizawa Y, Tanaka Y, et al. Long-term treatment with empagliflozin as add-on to oral antidiabetes therapy in Japanese patients with type 2 diabetes mellitus. Diabetes Obes Metab 2015;17(7):665-74.
38. Roden M, Merker L, Christiansen AV, et al. Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naive patients with type 2 diabetes: a doubleblind extension of a Phase III randomized controlled trial. Cardiovasc Diabetol 2015;14(1):154.
39. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999;281(21):2005-12.
40. Merker L, Häring HU, Christiansen AV, et al. Empagliflozin as add-on to metformin in people with type 2 diabetes. Diabet Med 2015;32(12):1555-67.
41. Garber AJ, Abrahamson MJ, Barzilay JI, et al. AACE/ACE comprehensive diabetes management algorithm 2015. Endocr Pract 2015;21(4):438-47.
42. Lewin A, DeFronzo RA, Patel S, et al. Initial combination of empagliflozin and linagliptin in subjects with type 2 diabetes. Diabetes Care 2015;38(3):394-402.
43. DeFronzo RA, Lewin A, Patel S, et al. Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin. Diabetes Care 2015;38(3):384-93.
44. Aronson R. Single-pill combination therapy for type 2 diabetes mellitus: linagliptin plus empagliflozin. Curr Med Res Opin 2015;31(5):901-11.
45. Fitchett D, Zinman B, Wanner C, et al. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME trial. Eur Heart J 2016; 37(19):1526-34.
46. Rossetti L, Smith D, Shulman GI, Papachristou D, DeFronzo RA. Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. J Clin Invest 1987;79(5):1510-5.
47. McCrimmon RJ, Evans ML, Jacob RJ, et al. AICAR and phlorizin reverse the hypoglycemia-specific defect in glucagon secretion in the diabetic BB rat. Am J Physiol Endocrinol Metab 2002;283(5):E1076-83.
48. Han S, Hagan DL, Taylor JR, et al. Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes 2008;57(6):1723-9.
49. Geerlings S, Fonseca V, Castro-Diaz D, List J, Parikh S. Genital and urinary tract infections in diabetes: impact of pharmacologically-induced glucosuria. Diabetes Res Clin Pract 2014;103(3):373-81.
50. Kim G, Gerich JE, Salsali A, et al. Empagliflozin (EMPA) increases genital infections but not urinary tract infections (UTIs) in pooled data from four pivotal phase III trials. Diabetes 2013;62(Supplement 1):LB21 (Abstract 74-LB).
51. Hach T, Gerich J, Salsali A, et al. Empagliflozin improves glycemic parameters and cardiovascular risk factors in patients with type 2 diabetes (T2DM): pooled data from four pivotal phase III trials. Diabetes 2013;62(Supplement 1):Abstract 69-LB.
52. Inzucchi SE, Zinman B, Wanner C, et al. SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials. Diab Vasc Dis Res 2015;12(2):90-100.
53. Kohler S, Salsali A, Hantel S, Kim G, Woerle HJ, Broedl UC. Safety and tolerability of empagliflozin in patients with type 2 diabetes. Diabetes Care 2015;64(suppl 1)(Poster 1173):Abstract
54. Taylor SI, Blau JE, Rother KI. Possible adverse effects of SGLT2 inhibitors on bone. Lancet Diabetes Endocrinol 2015;3(1):8-10.
55. US Food and Drug Administration. FDA Drug Safety Communication: FDA revises label of diabetes drug canagliflozin (Invokana, Invokamet) to include updates on bone fracture risk and new information on decreased bone mineral density. 2015. Available from: http://www.fda.gov/Drugs/DrugSafety/ucm461449.htm. Accessed: 18 January 2016.
56. Bilezikian JP, Watts NB, Usiskin K, et al. Evaluation of bone mineral density and bone biomarkers in patients with type 2 diabetes treated with canagliflozin. J Clin Endocrinol Metab 2016;101(1):44-51.
57. Janssen Pharmaceuticals Inc. Invokana® (canagliflozin) tablets, for oral use prescribing information (12/2015). Available from: https://www.invokana.com/prescribing-information.pdf. Accessed: 28 January 2016.
58. Wanner C, Toto RD, Gerich J, et al. No increase in bone fractures with empaglifl ozin (EMPA) in a pooled analysis of more than 11,000 patients with type 2 diabetes (T2DM). J Am Society Nephrol 2013;24(Supplement):205A (Abstract TH-PO452).
59. European Medicines Agency. Summary of the risk management plan (RMP) for Jardiance (empagliflozin). April 2014. Available from: http://www.fimea.fi/documents/542809/835259/27456_ Jardiance:RMP_summary-EN.pdf. Accessed: 18 January 2016.
60. European Medicines Agency. Jardiance: Assessment report. March 2014. Available from: http://www.ema.europa.eu/docs/en_GB/ document_library/EPAR_-_Public_assessment_report/human/002677/WC500168594.pdf. Accessed: 18 January 2016.
61. Rosenstock J, Ferrannini E. Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors. Diabetes Care 2015;38(9):1638-42.
62. Taylor SI, Blau JE, Rother KI. SGLT2 inhibitors may predispose to ketoacidosis. J Clin Endocrinol Metab 2015;100(8):2849-52.
63. Roach P, Skierczynski P. Euglycemic diabetic ketoacidosis in a patient with type 2 diabetes after treatment with empagliflozin. Diabetes Care 2016;39(1):e3.
64. Peters AL, Buschur EO, Buse JB, Cohan P, Diner JC, Hirsch IB. Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care 2015;38(9):1687-93.
65. Yabe D, Nishikino R, Kaneko M, Iwasaki M, Seino Y. Short-term impacts of sodium/glucose co-transporter 2 inhibitors in Japanese clinical practice: considerations for their appropriate use to avoid serious adverse events. Expert Opin Drug Saf 2015;14(6):795-800.
66. US Food and Drug Administration. Drug safety communication (05 May 2015): FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood. Available from: http://www.fda.gov/downloads/Drugs/DrugSafety/ UCM446954.pdf. Accessed: 13 January 2016.
67. European Medicines Agency. Review of diabetic medicines called SGLT2 inhibitors started (12 June 2015). Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Referral s_document/SGLT2_inhibitors__20/Procedure_started/WC500187926.pdf. Accessed: 24 June 2015.
68. American Diabetes Association. Standards of medical care in diabetes - 2016. Diabetes Care 2016;39(suppl 1):1-119.
69. Handelsman Y, Bloomgarden ZT, Grunberger G, et al. American Association of Clinical Endocrinologists and American College of Endocrinology - clinical practice guidelines for developing a diabetes mellitus comprehensive care plan - 2015. Endocr Pract 2015;21 Suppl 1:1-87.
70. Boehringer Ingelheim Pharmaceuticals Inc. Glyxambi® (empagliflozin and linagliptin), for oral use prescribing information (12/2015). Available from: http://docs.boehringeringelheim. com/Prescribing%20Information/PIs/Glyxambi/Glyxam bi.pdf. Accessed: 21 December 2015.
71. Pieber TR, Famulla S, Eilbracht J, et al. Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4-week, randomized, placebo-controlled trial (EASE-1). Diabetes Obes Metab 2015;17(10):928-35.
72. Perkins BA, Cherney DZ, Partridge H, et al. Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial. Diabetes Care 2014;37(5):1480-3.
73. Cherney DZ, Perkins BA, Soleymanlou N, et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 2014;129(5):587-97.
74. Häring HU, Merker L, Christiansen AV, et al. Empagliflozin as add-on to metformin plus sulphonylurea in patients with type 2 diabetes. Diabetes Res Clin Pract 2015;110(1):82-90